Curcumin and Metformin Infinite Coordination Polymer Nanoparticles for Combined Therapy of Diabetic Mice Via Intraperitoneal Injections

Overview

Journal J Funct Biomater

Specialty Biomedical Engineering

Date 2024 Dec 27

PMID 39728188

Authors

Siwei Sun

Xinyi Hou

Ke Li

Chenqi Huang

Yu Rong

Jiao Bi

Xueping Li

Daocheng Wu

Affiliations

Soon will be listed here.

Abstract

Metformin (Met) is one of the most commonly prescribed first-line drugs for diabetes treatment. However, it has several issues, including low bioavailability, therapeutic platform, and side effects at high doses. In order to improve the therapeutic efficiency of Met, this study proposes a strategy of using Met and curcumin (Cur) to prepare Cur-Zn(II)-Met infinite coordination polymer nanoparticles (CM ICP NPs), and combining this with intraperitoneal injections, for the treatment of diabetic mice. Fourier transform infrared (FTIR) spectroscopy, X-ray photoelectron spectroscopy (XPS), transmission electron microscopy (TEM), nanoparticle analysis, cytotoxicity experiments, and mice experiments were used to investigate structure, properties, and application effects. The results showed that CM ICP NPs exhibit a high drug encapsulation rate (100%), good stability, and an absence of in vivo and in vitro toxicity. The blood glucose level of diabetic mice after treatment was reduced to 6.7 ± 0.65 mmol/L at the seventh week. In terms of therapeutic mechanism, it appears that Met and Cur can synergistically regulate blood glucose in mice from multiple paths. This study provides a promising method for the treatment of diabetes using Met and other drugs.

References

Zhu H, Huang C, Di J, Chang Z, Li K, Zhang S . Doxorubicin-Fe(III)-Gossypol Infinite Coordination Polymer@PDA:CuO Composite Nanoparticles for Cost-Effective Programmed Photothermal-Chemodynamic-Coordinated Dual Drug Chemotherapy Trimodal Synergistic Tumor Therapy. ACS Nano. 2023; 17(13):12544-12562. DOI: 10.1021/acsnano.3c02401. View

Lashen H . Role of metformin in the management of polycystic ovary syndrome. Ther Adv Endocrinol Metab. 2012; 1(3):117-28. PMC: 3475283. DOI: 10.1177/2042018810380215. View

Vidon N, Chaussade S, Noel M, Franchisseur C, Huchet B, BERNIER J . Metformin in the digestive tract. Diabetes Res Clin Pract. 1988; 4(3):223-9. DOI: 10.1016/s0168-8227(88)80022-6. View

Xu M, Qi Y, Liu G, Song Y, Jiang X, Du B . Size-Dependent Transport of Nanoparticles: Implications for Delivery, Targeting, and Clearance. ACS Nano. 2023; 17(21):20825-20849. DOI: 10.1021/acsnano.3c05853. View

Pivari F, Mingione A, Brasacchio C, Soldati L . Curcumin and Type 2 Diabetes Mellitus: Prevention and Treatment. Nutrients. 2019; 11(8). PMC: 6723242. DOI: 10.3390/nu11081837. View

Mariano F, Biancone L . Metformin, chronic nephropathy and lactic acidosis: a multi-faceted issue for the nephrologist. J Nephrol. 2020; 34(4):1127-1135. PMC: 8357762. DOI: 10.1007/s40620-020-00941-8. View

Xue C, Chen Y, Bi Y, Yang X, Chen K, Tang C . Dilemmas in Elderly Diabetes and Clinical Practice Involving Traditional Chinese Medicine. Pharmaceuticals (Basel). 2024; 17(7). PMC: 11279884. DOI: 10.3390/ph17070953. View

Huang Z, Wang Y, Yao D, Wu J, Hu Y, Yuan A . Nanoscale coordination polymers induce immunogenic cell death by amplifying radiation therapy mediated oxidative stress. Nat Commun. 2021; 12(1):145. PMC: 7794559. DOI: 10.1038/s41467-020-20243-8. View

Khodadadi M, Jafari-Gharabaghlou D, Zarghami N . An update on mode of action of metformin in modulation of meta-inflammation and inflammaging. Pharmacol Rep. 2022; 74(2):310-322. DOI: 10.1007/s43440-021-00334-z. View

10.

Jin H, Wang L, Bernards R . Rational combinations of targeted cancer therapies: background, advances and challenges. Nat Rev Drug Discov. 2022; 22(3):213-234. DOI: 10.1038/s41573-022-00615-z. View

11.

Nahar N, Mohamed S, Mustapha N, Lau S, Mohd Ishak N, Umran N . Metformin attenuated histopathological ocular deteriorations in a streptozotocin-induced hyperglycemic rat model. Naunyn Schmiedebergs Arch Pharmacol. 2020; 394(3):457-467. DOI: 10.1007/s00210-020-01989-w. View

12.

Kim J, Eygeris Y, Ryals R, Jozic A, Sahay G . Strategies for non-viral vectors targeting organs beyond the liver. Nat Nanotechnol. 2023; 19(4):428-447. DOI: 10.1038/s41565-023-01563-4. View

13.

Chen Y, Huang G, Qin T, Zhang Z, Wang H, Xu Y . Ferroptosis: A new view on the prevention and treatment of diabetic kidney disease with traditional Chinese medicine. Biomed Pharmacother. 2023; 170:115952. DOI: 10.1016/j.biopha.2023.115952. View

14.

Kirpichnikov D, McFarlane S, Sowers J . Metformin: an update. Ann Intern Med. 2002; 137(1):25-33. DOI: 10.7326/0003-4819-137-1-200207020-00009. View

15.

Chan H, Chow S, Zhang X, Kwok P, Chow S . Role of Particle Size in Translational Research of Nanomedicines for Successful Drug Delivery: Discrepancies and Inadequacies. J Pharm Sci. 2023; 112(9):2371-2384. DOI: 10.1016/j.xphs.2023.07.002. View

16.

Hassan I, Al-Tamimi J, Ebaid H, Habila M, Alhazza I, Rady A . Silver Nanoparticles Decorated with Curcumin Enhance the Efficacy of Metformin in Diabetic Rats via Suppression of Hepatotoxicity. Toxics. 2023; 11(10). PMC: 10611133. DOI: 10.3390/toxics11100867. View

17.

Fukui M, Song J, Choi J, Choi H, Zhu B . Mechanism of glutamate-induced neurotoxicity in HT22 mouse hippocampal cells. Eur J Pharmacol. 2009; 617(1-3):1-11. DOI: 10.1016/j.ejphar.2009.06.059. View

18.

Oliveira W, Braga C, Los D, Araujo S, Franca M, Duarte-Silva E . Metformin prevents p-tau and amyloid plaque deposition and memory impairment in diabetic mice. Exp Brain Res. 2021; 239(9):2821-2839. DOI: 10.1007/s00221-021-06176-8. View

19.

Roxo D, Arcaro C, Gutierres V, Costa M, Oliveira J, Lima T . Curcumin combined with metformin decreases glycemia and dyslipidemia, and increases paraoxonase activity in diabetic rats. Diabetol Metab Syndr. 2019; 11:33. PMC: 6492331. DOI: 10.1186/s13098-019-0431-0. View

20.

Tikoo K, Meena R, Kabra D, Gaikwad A . Change in post-translational modifications of histone H3, heat-shock protein-27 and MAP kinase p38 expression by curcumin in streptozotocin-induced type I diabetic nephropathy. Br J Pharmacol. 2008; 153(6):1225-31. PMC: 2275435. DOI: 10.1038/sj.bjp.0707666. View